Intelligence · Clinical Development
Pipeline search results
Programs matching “cemiplimab” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 52 pipeline programs matching "cemiplimab" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Cemiplimab
Regeneron UK Limited
HIV Infections
1 trial -
Cemiplimab
Regeneron UK Limited
Cervical Cancer
1 trial -
Cemiplimab
Regeneron UK Limited
Colo-rectal Cancer
1 trial -
Cemiplimab
Regeneron UK Limited
Colon and Rectal Cancer
1 trial -
Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]
Regeneron UK Limited
Colon Cancer
1 trial -
Cemiplimab 350 MG Intravenous Solution
Regeneron UK Limited
Clear Cell Renal Cell Carcinoma
1 trial -
Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cycles
Regeneron UK Limited
Merkel Cell Carcinoma, Stage I
1 trial -
Cemiplimab Plus Gemcitabine
Regeneron UK Limited
Pancreatic Ductal Adenocarcinoma (mPDAC)
1 trial -
Cemiplimab-Rwlc
Regeneron UK Limited
Non-small Cell Lung Cancer Stage III
1 trial -
Cemiplimab-Rwlc
Regeneron UK Limited
Cutaneous Squamous Cell Carcinoma
2 trials -
Cemiplimab-Rwlc
Regeneron UK Limited
Head and Neck Squamous Cell Carcinoma
1 trial -
FDC fianlimab+cemiplimab
Regeneron UK Limited
Head and Neck Squamous Cell Carcinoma (HNSCC)
1 trial -
Fianlimab+cemiplimab
Regeneron UK Limited
Melanoma
1 trial -
cemiplimab
Regeneron UK Limited
Cutaneous Basal Cell Carcinoma
1 trial -
cemiplimab
Regeneron UK Limited
Advanced Cutaneous Squamous Cell Carcinoma
1 trial -
cemiplimab
Regeneron UK Limited
Melanoma
1 trial -
cemiplimab
Regeneron UK Limited
Carcinoma, Basal Cell
1 trial -
cemiplimab (monotherapy)
Regeneron UK Limited
Relapsed Solid Tumor
1 trial -
Arm 1 cemiplimab
Regeneron UK Limited
Hepatocellular Carcinoma
1 trial -
Cemiplimab
Regeneron UK Limited
Epithelial Ovarian Cancer
1 trial -
Cemiplimab
Regeneron UK Limited
Hormone Receptor-positive Breast Cancer
1 trial -
Cemiplimab
Regeneron UK Limited
Advanced Cancer
1 trial -
Cemiplimab
Regeneron UK Limited
Advanced Malignancies
1 trial -
Cemiplimab
Regeneron UK Limited
Anaplastic Thyroid Cancer
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.